Targeted gene delivery: A two-pronged approach

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 17, Issue 4, 2000, Pages 377-424

  Anwer, Khursheed ^a,b   Bailey, Austin ^b   Sullivan, Sean M ^b  

^a Expression Genetics Inc   (United States)

^b Urigen Pharmaceuticals Inc   (United States)

Author keywords

Adeno associated virus; Adenovirus; Cationic liposomes; Cationic polymers; Gene therapy; Nonviral; Retrovirus; Viral

Indexed keywords

CELL SURFACE RECEPTOR; LIPOSOME; PLASMID DNA; POLYMER;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE TARGETING; GENE TRANSFER; GENETIC DISORDER; GENETIC TRANSFECTION; LIGAND BINDING; PROMOTER REGION; RETROVIRUS; REVIEW; TARGET CELL;

EID: 0033836032     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v17.i4.30     Document Type: Review

References (194)

1. Human gene therapy comes of age
2. The basic science of gene therapy
3. Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retro-virus are inducible sodium-dependent phosphate transporters
4. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and non-mammalian cells
5. Modifying the host range properties of retroviral vectors
6. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types
7. Inverse targeting of retroviral vectors: Selective gene transfer in a mixed population of hematopoietic and non-hematopoietic cells
8. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies
9. Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery
10. Efficient gene delivery to quiescent interleukin-2 (IL-2)-dependent cells by murine leukemia virus-derived vectors harboring IL-2 chimeric envelope glycoproteins
11. Targeting retroviral vectors to vascular lesions by genetic engineering of the Mo-MLV gp70 envelope Protein
12. Targeting retroviral vectors to specific cells
13. Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins
14. The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system
15. Identification of the block in targeted retroviral-medicated gene transfer
16. The role of the adenovirus protease on virus entry into cells
17. Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway
18. Adenovirus-mediated gene therapy of liver diseases
19. p53 Gene therapy in a rat model of hepatocellular carcinoma: Intra-arterial delivery of a recombinant adenovirus
20. Efficient mitochondrial import of newly synthesized ornithine transcarbamylase (OTC) and correction of secondary metabolic alterations in spf(ash) mice following gene therapy of OTC deficiency
21. In vivo evaluation of an adenoviral vector encoding canine factor VIII: High-level, sustained expression in hemophiliac mice
22. Targeted gene delivery by tropism-modified adenoviral vectors
23. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor
24. Use of a novel cross-linking method to modify adenovirus tropism
25. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer
26. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor
27. Identification of conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae
28. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions
29. Alpha Vbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection
30. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
31. Adeno-associated viral vectors for gene transfer and gene therapy
32. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
33. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats
34. Targeted adeno-associated virus vector transduction of non-permissive cells mediated by a bispecific F(ab'gamma)2 antibody
35. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
36. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure
37. Monoclonal antibody and liposomes
38. Plasmid DNA adsorbed to pH-sensitive liposomes efficiently transforms the target cells
39. Highly efficient DNA delivery mediated by pH-sensitive immunoliposomes
40. pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse
41. Growth inhibition of glioma cells transfected with the human b-interferon gene by liposomes coupled with a monoclonal antibody
42. Gene transfer from targeted liposomes to specific lymphoid cells by electroporation
43. Anti-HER2 immunoliposomes for targeted therapy of human tumors
44. Structure and function of transferrin receptors and their relationship to cell growth
45. Construction of transferrin-coated liposomes for in vivo transport of exogenous DNA to bone marrow erythroblasts in rabbits
46. Covalent modification of serum transferrin with phospholipid and incorporation into liposomal membranes
47. Receptor ligand-facilitated gene transfer: Enhancement of liposome-mediated gene transfer and expression by transferrin
48. Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides
49. Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro
50. Homing of liposomes to target cells
51. Specific incorporation of asialofetuin-labeled liposomes into hepatocytes through the action of galactose-binding protein
52. Receptor-mediated transfer of pSV2CAT DNA to mouse liver cells using asialofetuin-labeled liposomes
53. Effects of fusogenic and DNA-binding amphiphilic compounds on the receptor-mediated gene transfer into hepatic cells by asialofetuin-labeled liposomes
54. Use of targeted cationic liposomes in enhanced DNA delivery to cancer cells
55. Selection and use of ligands for receptor-mediated gene delivery to myogenic cells
56. Enhancement of transfection efficiency using ligand-modified lipid vesicles
57. Targeted delivery of DNA encoding cytotoxic proteins through high-affinity fibroblast growth factor receptors
58. Targeted gene transfer into hepatoma cells with llpopolyamine-condensed DNA particles presenting galactose ligands: A stage toward artificial viruses
59. Folate-binding protein is a marker for ovarian cancer
60. Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells
61. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer
62. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule
63. Lipid-mediated enhancement of transfection by a nonviral integrin-targeting vector
64. Liposomes enhance delivery and expression of an RGD-oligolysine gene transfer vector in human tracheal cells
65. Transfection ofEscherichia coli spheroplasts. III. Facilitation of transfection and stabilization of spheroplasts by different basic polymers
66. Use of N-terminal modified poly(L-lysine)-antibody conjugate as a carrier for targeted gene delivery in mouse lung endothelial cells
67. Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly(L-lysine)-antibody conjugate in mouse lung endothelial cells
68. Carbohydrate receptor-mediated gene transfer to human T leukemic cells
69. HER2-targeted gene transfer
70. In vitro targeting and specific transfection of human neuroblastoma cells by chCE7 antibody-mediated gene transfer
71. Antibody-mediated gene delivery for B-cell lymphoma in vitro
72. Gene transfer into the airway epithelium of animals by targeting the polymeric immunoglobulin receptor
73. Immunogene approach toward cancer therapy using erythrocyte growth factor receptor-mediated gene delivery
74. Targeted in vivo delivery of therapeutic gene into experimental squamous cell carcinomas using anti-epidermal growth factor receptor antibody: Immunogene approach
75. Gene transfer mediated by alpha2-macroglobulin
76. Targeting DNA to cells with basic fibroblast growth factor (FGF2)
77. Nonviral neuronal gene delivery mediated by the HC fragment of tetanus toxin
78. Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro
79. Receptor-mediated gene delivery and expression in vivo
80. Nonenzymatic glycosylation ofpoly-L-lysine: A new tool for targeted gene delivery
81. Targeted delivery of plasmid DNA complexed with galactosylated poly(L-lysine)
82. Targeted delivery of plasmid DNA to hepatocytes in vivo: Optimization of the phannacokinetics of plasmid DNA/galactosylated poly(L-lysine) complexes by controlling their physicochemical properties
83. Targeted Gene Delivery with a Low Molecular Weight Glycopeptide Carrier
84. Specific gene transfer based on biotinylated and gluconylated polylysine/plasmid complexes
85. Lactose-poly(ethylene glycol)-grafted poly-L-lysine as hepatoma cell- targeted gene carrier
86. Influenza fusogenic peptide in DNA complex enhances asialoglycoprotein receptor-mediated gene transfer to hepatoma cells: A strategy for liver- targeting gene therapy
87. Receptor-mediated gene transfer into macrophages
88. Gene transfer by DNA/glycosylated polylysine complexes into human blood monocyte-derived macrophages
89. Folate receptor mediated DNA delivery into tumor cells: Protosomal disruption results in enhanced gene expression
90. Transfection of folate-polylysine DNA complexes: Evidence for lysosomal delivery
91. Gene delivery and expression mediated by an integrin-binding peptide
92. Integrin-mediated transfection with peptides containing arginine-glycine-aspartic acid domains
93. An RGD-oligolysine peptide: A prototype construct for integrin-mediated gene delivery
94. Ligand substitution of receptor targeted DNA complexes affects gene transfer into hepatoma cells
95. A novel gene delivery system targeting cells expressing VEGF receptors
96. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery
97. In vitro gene delivery to hepatocytes with galactosylated polyethylenimine
98. Galactosylated histone-mediated gene transfer and expression
99. Transcriptional regulation of multigene loci
100. Scaffold/matrix attached regions: Topological switches with multiple regulatory functions. Crit. Rev. Eukaryot
101. Dissection of the ability of the chicken lysozyme gene 5' matrix attachment region to stimulate transgene expression and to dampen position effects
102. Transcriptional regulation of mammalian genes in vivo. A tale of two templates
103. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters
104. Liver-directed gene therapy: Evaluation of liver-specific promoter elements
105. Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes
106. Liver-directed gene therapy: A retroviral Vector with a complete LTR and the ApoE enhancer-a 1-antitrypsin promoter dramatically increases expression of human a 1-antitrypsin in vivo
107. Hepatic gene therapy: Persistent expression of human a-1antitrypsin in mice after direct gene delivery in vivo
108. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer
109. High-level tissue-specific expression of functional human factor VIII in mice
110. Persistent gene expression after retroviral gene transfer into liver cells in vivo
111. Expression of human a-1 antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes
112. Liver-directed gene therapy: Quantitative evaluation of promoter elements by using in vivo retroviral transduction
113. Evaluation of relative promoter strength in primary hepatocytes using optimized lipofection
114. Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus
115. Determinants of retrovirus gene expression in embryonal carcinoma cells
116. Retroviral vector sequences may interact with some internal promoters and influence expression
117. Gene transfer in vivo: Sustained expression and regulation of gene introduced into the liver by receptor-targeted uptake
118. Receptor-mediated gene delivery in vivo: Partial correction of gene analbuminemia in Nagase rats
119. Gene transfer in primary cultures of human hepatocytes
120. Expression of human factor IX in mice after injection of genetically modified myoblasts
121. Systemic delivery of growth hormone by injection of genetically engineered myoblasts
122. Muscle is the major source of plasma gelsolin
123. Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein
124. Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle
125. Direct gene transfer into mouse muscle in vivo
126. Direct gene transfer into nonhuman primate myofibers in vivo
127. Gene therapy by intramuscular injection of plasmid DNA: Studies on firefly luciferase gene expression in mice
128. Direct gene transfer into skeletal muscle in vlvo: Factors affecting efficiency of transfer and stability of expression
129. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle
130. Gene therapy and hemophilias
131. Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo
132. Pharmaceutical approach to somatic gene therapy
133. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector
134. Human genetic disease and the medical need for somatic gene therapy
135. Mdx Transgenic mouse: Restoration of recombinant dystrophin to the dystrophic muscle
136. Direct gene transfer in skeletal muscle: Plasmid DNA-based immunization against the hepatitis B surface antigen
137. Sequential expression of chicken actin genes during myogenesis
138. The chicken skeletal muscle a-actin promoter is tissue specific in transgenic mice
139. Myogenic vector expression of insulin-like growth factor-I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice
140. Systemic effect of human growth hormone after intramuscular injection of a single dose of a muscle-specific gene medicine
141. Synthetic muscle promoters: Activities exceeding naturally occurring regulatory sequences
142. Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/enhancer
143. Insertion of two independent enhancers in long terminal repeat of a self-inactivating vector results in high-titer retroviral vectors with tissue-specific expression
144. SEZ-6: Promoter selectivity, genomic structure and localized expression in the brain
145. Upstream elements involved in vivo inactivation of the brain-specific rataldolase C gene. Role of binding sites for POU and winding helix proteins
146. Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental parkinsonism
147. Selective gene therapy of malignant gliomas using brain-specific promoters: Its efficacy and basic investigations
148. Targeting gene expression to endothelial cells in transgenic mice using the human intracellular adhesion molecule 2 promoter
149. Use of two Willebrand factor promoter to transduce suicidal gene to human endothelial cells, HUVEC
150. Endothelial-specific gene expression directed by the tie gene promoter in vivo
151. In vivo angiogenesis induced by recombinant adenovirus vectors either for secreted or non-secreted forms of acidic fibroblast growth factor
152. Low efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit
153. Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector
154. Human Mn-superoxide dismutase in pulmonary epithelial cells of transgenic mice confers protection from oxygen injury
155. Lung-specific expression in mice of a dominant negative mutant form of the p53 tumor suppressor protein
156. Cell-specific expression of a Clara cell secretory protein-human growth hormone gene in the bronchiolar epithelium of transgenic mice
157. Tissue-specific expression of the gene coding for human Clara cell 10-kD protein, a phosphollpase A2-inhibitory protein
158. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters
159. Heart muscle-specific gene expression using replication defective recombinant adenovirus
160. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene
161. Combination gene therapy for liver metastases of colon carcinoma in vivo
162. Retroviral delivery of DNA into the liver of transgenic mice bearing premalignant and malignant hepatocellular carcinoma
163. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in nude mouse model
164. Liver-associated toxicity of the HSVtk/GCV approach and adenoviral vectors
165. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-feto-protein gene promoter
166. Retrovirus-mediated gene therapy for human hepatocellular carcinoma transplanted in athymic mice
167. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus, mediated transfer of the herpes simplex virus thymidine kinase gene
168. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2
169. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector
170. Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene
171. Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice
172. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro
173. Tumor-specific gene expression in carcinoembryonic antigen-producing gastric cancer cells using adenovirus vectors
174. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma
175. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach
176. Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo
177. Selective expression of carcinoembryonic antigen promoter in cancer cell lines: Targeting strategy for gene therapy in colorectal cancer
178. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer
179. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen
180. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene
181. Microphthalmia-associated transcription of the human tyrosinase gene
182. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nudeoside phosphorylase gene in melanoma
183. A safe, effective in vivo gene therapy for melanoma using tyrosinase promoter-driven cytosine deaminase gene
184. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanoma following direct intratumoral injection of DNA
185. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir
186. A regulatory system for use in gene transfer
187. Ligand-inducible and liver-specific target gene expression in transgenic mice
188. Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator
189. Adenovirus-mediated regulateable target gene expression in vivo
190. Tight control of gene expression in mammalian cells by tetracyclin-responsive promoters
191. Ecdysone-inducible gene expression in mammalian cells and transgenic mice
192. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer
193. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer